Last reviewed · How we verify
Moderate to severe axillary hidradenitis suppurativa
Approved treatments
- Chronic- PF-06480605 450 mg SC Q4W · Pfizer
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe axillary hidradenitis suppurativa patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe axillary hidradenitis suppurativa treatment landscape brief
- Moderate to severe axillary hidradenitis suppurativa treatment updates RSS
Frequently asked questions about Moderate to severe axillary hidradenitis suppurativa
What drugs treat Moderate to severe axillary hidradenitis suppurativa?
Tracked treatments include Chronic- PF-06480605 450 mg SC Q4W.
What is the treatment for Moderate to severe axillary hidradenitis suppurativa?
Standard treatment for Moderate to severe axillary hidradenitis suppurativa includes Chronic- PF-06480605 450 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe axillary hidradenitis suppurativa patent cliff · Moderate to severe axillary hidradenitis suppurativa CI report
- Treatment: Chronic- PF-06480605 450 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing